{"name":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","slug":"fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii","ticker":"","exchange":"","domain":"","description":"The Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III is a leading research institution focused on cardiovascular diseases, contributing significantly to the advancement of medical knowledge and the development of innovative treatments.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cardiovascular Polypill","genericName":"Cardiovascular Polypill","slug":"cardiovascular-polypill","indication":"Cardiovascular disease prevention and secondary prevention in high-risk patients","status":"phase_3"},{"name":"Treatment Prevention for Secondary CV","genericName":"Treatment Prevention for Secondary CV","slug":"treatment-prevention-for-secondary-cv","indication":"Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"FDC","genericName":"FDC","slug":"fdc","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Cardiovascular Polypill","genericName":"Cardiovascular Polypill","slug":"cardiovascular-polypill","phase":"phase_3","mechanism":"A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects.","indications":["Cardiovascular disease prevention and secondary prevention in high-risk patients"],"catalyst":""},{"name":"FDC","genericName":"FDC","slug":"fdc","phase":"phase_3","mechanism":"FDC is a cardiovascular investigational drug developed by a Spanish research foundation, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"Treatment Prevention for Secondary CV","genericName":"Treatment Prevention for Secondary CV","slug":"treatment-prevention-for-secondary-cv","phase":"phase_3","mechanism":"This drug targets the PCSK9 protein to lower LDL cholesterol levels.","indications":["Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}